Early prognostic stratification is desirable in patients with suspected atypical parkinsonian syndromes (APS) for optimal treatment and counseling. We investigated the prognostic value of imaging disease-specific metabolism patterns with 18 F-FDG PET compared to the clinical diagnosis. 
INTRODUCTION
Early differentiation between Parkinson's disease (PD) and atypical parkinsonian syndromes (APS; including multiple system atrophy [MSA] , progressive supranuclear palsy [PSP] , and corticobasal degeneration [CBD] ) is pursued for decisions on treatment strategies and prognostic counseling. APS are characterized by a rapid progression to disability and death. According to clinical and clinicopathological studies, MSA, PSP, and CBD share a comparably short survival of about 7-8 years from symptom onset or less than 3-4 years from clinical diagnosis (1) (2) (3) (4) (5) (6) (7) (8) . Survival in PD is distinctly better: While some population-based studies did not find higher mortality (e.g.,
9)
, others convincingly demonstrated an increased age-adjusted mortality in PD (10, 11) . As in APS (1, 2, 5, 8) , higher age at onset is also associated with a higher PD mortality (9, 10) , but median survival time was still 10.3 years in a recent populationbased cohort with a high average age of 70 years at diagnosis (9) . The cumulative incidence of PD with dementia (PDD) increases with age and disease duration up to 80-90% (12) , being associated with a strong increase in mortality (9) (10) (11) . In fact, the mean time span between onset of cognitive impairment and death appears to be only about 2-4 years (12) (13) (14) .
Disease-specific patterns of regional cerebral glucose metabolism depicted by positron emission tomography with [ 18 F]fluorodeoxyglucose ( 18 F-FDG PET) allow for an accurate differential diagnosis between PD and APS (15) (16) (17) . Moreover, PDD is characterized by posterior cortical hypometabolism, which is also observed in a significant fraction of non-demented PD patients (16) . Recent studies suggest that this pattern may herald the conversion from PD to PDD and thus rapid deterioration (reviewed in 18). Given the high concordance between PET and clinical diagnoses (about 80% for the aforementioned groups) (16) , it may be expected that disease-specific PET patterns by on . For personal use only. jnm.snmjournals.org Downloaded from 5 also carry prognostic information. However, this rational is challenged by the limited accuracy of the clinical diagnosis compared to the diagnosis at autopsy (70-75%) (4, (19) (20) (21) (22) (23) , which implies that the correctness of the diagnosis/prognosis given by PET is illdefined at the moment (55-95%).
Against this background, we investigated whether 18 F-FDG PET provides an early prediction of survival in patients with clinically suspected APS. Patients with suspected APS at study inclusion underwent a follow-up of up to 5.9 years after prospective 18 F-FDG PET imaging. We compared the prognostic value of 18 F-FDG PET performed at baseline and of the clinical diagnosis finalized after a median follow-up of 1 year.
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MATERIALS AND METHODS

Study Design and Patients
The present study population has been reported before (16) . Patient flow is summarized in Figure 1 . Ninety-five of 107 patients referred for diagnostic imaging between July 2008 and January 2011 for clinically suspected, but not yet verified early-stage APS (based on clinical symptoms and poor response to levodopa; Karnofsky score ≥40%) gave written informed consent.
After a median follow-up of 12 months (minimum 6 months) two board-certified neurologists specialized in movement disorders and blinded for aforementioned imaging results made the clinical diagnosis in accordance to consensus criteria (16, 24) . Seventeen patients were excluded from the comparison of the prognostic values of 18 F-FDG PET and 1-year follow-up diagnosis , because the latter indicated a diagnosis other than APS or Lewy body diseases (LBD; i.e., PD, PDD, and dementia with Lewy bodies [DLB]). Thus, 78 patients (n = 44 APS, n = 34 LBD) were retained. Patients' characteristics are summarized in Table 1 . As previously suggested (16) , patients with the clinical diagnosis of PDD and DLB were allocated to a combined group (PDD/DLB), opposed to non-demented PD. Likewise, we also used a combined PSP/CBD diagnosis group for the present analyses given the uncertainty of differentiating between these two diseases by clinical or imaging findings. At time of imaging, there were no significant group differences in terms of sex, symptom duration, or Unified Parkinson's Disease Rating Scale motor (part III) score. In line with the clinical diagnoses, APS patients showed higher Hoehn & Yahr (H&Y) scores than PD patients. Furthermore, PD patients were significantly younger than PDD/DLB patients, whereas PDD/DLB patients showed a significantly lower Mini-Mental State Examination (MMSE) score than PD and MSA patients (see Table 1 ). For the purpose of the present study, a movement disorders specialist conducted a structured telephone interview with the patient, the caregiver and/or the care-giving physician (as appropriate) in September 2014. The vital status and the need for longterm professional care were systematically recorded. Overall disease severity was assessed by the H&Y score (range 1-5, with higher scores indicating greater impairment) (25) . The level of functional independence was evaluated using the Schwab and England activities of daily living scale (ADL; range 0-100, with lower scores reflecting greater disease burden) (26).
18
F-FDG PET
PET scans were acquired and analyzed as described previously (16) . In brief, PET scans were independently interpreted by two investigators with long-standing clinical experience in brain PET imaging who were blinded to clinical data. The investigators rated standardized transaxial and sagittal PET images and three-dimensional stereotactic surface projections (3D-SSP) depicting each individual's cerebral 18 F-FDG uptake (glucose metabolism) and its statistical deviation from a database of agematched healthy controls (Neurostat/3D-SSP) (27) . PET scans were interpreted in two consecutive levels using a-priori defined disease-specific patterns (16) 
Study Approval
All procedures were approved by the local ethics committee. Written informed consent was obtained from all participants. The initial study was registered at the German Clinical Trials Register (DRKS00003613).
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RESULTS
Survival Analyses
A total of 34 patients died during follow-up, 44 patients were still alive at final contact.
Median follow-up duration was 4.77 years (95% CI 4.44 -5.10; estimated by the reverse Kaplan-Meier method (28)). Table 2 showed a significantly worse survival than patients with PD, whereas there was no significant difference in survival between PDD/DLB (p=0.647, Chi 2 =0.2) and PD ( Figure   2E ). Median survival time was reached for PSP/CBD (3.86 years after PET for both classifications) and MSA (4.74 years for both classifications), while median survival time was not reached for PDD/DLB (Table 2) . Interestingly, survival curves of patients with by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from congruent PET and clinical classifications (62/78 or 79.5% patients) were very similar to those provided by PET alone ( Figure 2F ). Table 3 gives an overview of survival data of patients with discrepant PET and follow-up clinical diagnoses. Albeit vital status and neurological performance at last contact (given by H&Y or ADL score) suggest correct prognostic classification by either PET or followup clinical diagnosis in some cases, no clear systematic pattern is apparent given the limited number of discrepant cases.
Cox Proportional Hazards Model
Age-adjusted hazard ratios (HR) for 1 st -level and 2 nd -level classifications as predictors for overall survival are also given in Table 2 . Regression analyses indicated a significantly higher age-adjusted mortality for patients classified as APS (1 st -level decision) with a HR of 3.81 for PET and 3.85 for 1-year follow-up (HR relative to LBD).
Regarding 2 nd -level decisions, being classified as PSP/CBD by PET (HR=5.15; relative to PD) or by 1-year follow-up (HR=4.46) was associated with significantly increased mortality. In contrast, a diagnosis of MSA was a significant predictor of worse ageadjusted survival only for PET (HR=5.64) but not for 1-year follow-up (HR=2.80). The age-adjusted HR for patients with a PDD/DLB-suggestive hypometabolism on PET (HR=2.01) tended to be higher than the HR for patients clinically diagnosed with PDD/DLB (HR=1.05), but neither group exhibited a statistically significant higher ageadjusted mortality than PD. In direct comparisons, aforementioned differences in HR between PET and 1-year follow-up diagnosis did not reach statistical significance (neither 1 st nor the 2 nd level). As may be expected (highest diagnostic confidence), a congruent PET and clinical classification was consistently associated with a higher ageadjusted HR than for each of the two classifiers alone (see Table 2 ).
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Finally, when all 95 patients (including those 17 patients which had been excluded from the main analysis because of alternative clinical diagnoses, see Figure 1 ) were subjected to an intention-to-treat analysis of the prognostic value of PET, results remained essentially unchanged (see Table 2 ).
DISCUSSION
The present study demonstrates that 18 To our knowledge, this study is the first to compare the prognostic value of PET and clinical diagnosis. Except for few individual cases (e.g., 17), a systematic validation of PET classifications against post mortem histopathology has not been accomplished.
Considering the limited accuracy of clinical diagnosis of about 70-75% for PD (19-21)
by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from or APS (even worse for CBD) (4, 20, 22, 23) , the use of clinical diagnoses as reference standard constitutes a central limitation of all previous diagnostic PET studies. The present study circumvents this limitation by focussing on prognosis and selecting the most important, hard clinical endpoint. Thereby we demonstrate that PET is a prognostic marker on its own. However, the good agreement between the diseasespecific survival data of the present PET study and earlier post mortem studies also provides indirect support to the notion that metabolic patterns are valuable means for differential diagnosis (2-5, 7, 13 ).
Of note, we included only patients with an uncertain initial diagnosis because PET would be most useful in these patients, who represent an often encountered initial clinical dilemma. Thus, albeit we have access to an early PET scan, we do not have access to a proper initial clinical diagnosis. Given the lack of an initial clinical diagnosis, we explored the possible prognostic value of general disease severity (not shown in detail): Including the H&Y stage at time of PET as a marker of disease severity into multivariate analyses did only marginally affect the prognostic value of 18 F-FDG PET (HR 3.4, 4.5 and 5.0 for APS, PSP/CBD and MSA, respectively). Similarly, dysphagia or the presence of falls during the first year essentially did not alter the prognostic value of 18 F-FDG PET (HR 3.7, 5.1 and 5.5 for APS, PSP/CBD and MSA, respectively). In addition, we tried to enhance our prediction models by including regional PET analyses (normalized 18 F-FDG uptake of striatum, cerebellum, thalamus, major lobes as well as the frontal/parietooccipital uptake ratio). Relative regional metabolism of cerebellum, striatum and frontal, temporal and parietal lobes predicted survival at least at trend level (p<0.1). However, when regional variables were included into models with visual PET pattern classifications (1 st -or 2 nd -level), only visual PET classifications and age remained significant predictors of survival.
We contemplated a combined PSP/CBD group. PSP and CBD are considered to belong to the same disease spectrum with several common clinical, pathological, genetic and biochemical features (29) . Consequently, clinical distinction between PSP and CBD can be very challenging with frequent misdiagnoses in both directions (4, 30) .
Likewise, PET imaging patterns in patients with the clinical diagnoses of PSP and CBD may be very similar and distinctive features are still matter of debate (31) (32) (33) . Of note, median survival time in PSP and CBD were not significantly different (neither for PET nor for clinical diagnosis). We also used a combined PDD/DLB grouping, since the clinical distinction between PDD and DLB is controversial and metabolic patterns in PDD and DLB show only very subtle differences (if any) (34) . Of note, a PET classification according to the presence of a PDD/DLB-suggestive hypometabolism does not only include patients with manifest PDD or DLB (as for clinical classification), but may also include a significant fraction of non-demented PD patients with probably increased risk of dementia and thus worse prognosis (reviewed in 18). Preceding posterior cortical hypometabolism at a non-demented stage has been described in patients who later converted to DLB (35) and PDD (36) . Furthermore, patients with PD and mild cognitive impairment (PD-MCI), who are at increased risk of dementia exhibit decreased cortical metabolism similar to that seen in PDD (18) . Therefore, if a dichotomization between PD and PDD/DLB is pursued, PET may be expected to provide a better prognostic stratification than the clinical diagnosis. On the other hand, using a combined clinical PDD/DLB classification may not be ideal for prognostic statements, since earlier studies suggest that overall survival from onset of dementia may be shorter in PDD than DLB (9, 12, 13) . Taken together, a simple dichotomization probably does not take full advantage of the combined prognostic potential of PET and clinical findings. We did not attempt to unravel the contributions of clinical diagnosis, cognitive status and PET finding to predicting survival in patients with LBD since no by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from 14 comprehensive and standardized cognitive assessment was performed at study entry. by on November 7, 2017. For personal use only. jnm.snmjournals.org Downloaded from Results from intention to treat analyses comprising all 95 patients who gave their consent to participate.
TABLES
Abbreviations: 95% CI, 95% confidence interval; for additional abbreviations see Figure 1 .
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